fda glp-1 warning november 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded Drugs and Telehealth Providers GLP-1s in 2026: What Brokers
Description
2 Medicare Part D currently covers GLP-1/GIP agonists that are FDA approved for type 2 diabetes and cardiovascular disease
"There is no evidence to indicate that patients will completely regain all the weight after stopping the medication
The common denominator is the same class of medications: GLP-1 receptor agonists , drugs used for diabetes and weight loss
Internet J Endocrinol
The drugs were initially intended to treat type 2 diabetes, but are increasingly used for weight loss and chronic weight management, health officials say
J Am Pharm Assoc 65:102385
